BUZZ-H.C. Wainwright initiates Senti Biosciences with 'Buy' on cell therapy hopes

Reuters10-14

BUZZ-H.C. Wainwright initiates <a href="https://laohu8.com/S/SNTI">Senti Biosciences</a> with 'Buy' on cell therapy hopes

** Shares of cancer therapies developer Senti Biosciences SNTI.O rise 1.1% to $1.70 in premarket

** H.C. Wainwright starts coverage with "Buy" rating and price target $12, a ~614% upside to the stock's last close

** Brokerage says Senti's new cell therapy helped patients with tough-to-treat blood cancer

** It believes co's therapy platform "has the potential to treat several cancer types, including hematologic malignancies and solid tumors"

** SNTI is developing a cell therapy to treat acute myeloid leukemia, a fast-growing blood cancer with limited treatment options

** 2 of 2 brokerages rate the stock 'buy' or higher, none 'hold' or 'sell'; their median price target is $13.50

** Up to last close, stock has fallen ~52% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2575213041?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-14 21:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575213041","market":"nz","top_or_hot":-1,"title":"BUZZ-H.C. Wainwright initiates Senti Biosciences with 'Buy' on cell therapy hopes","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-H.C. Wainwright initiates <a href=\"https://laohu8.com/S/SNTI\">Senti Biosciences</a> with 'Buy' on cell therapy hopes</title></head><body><p>** Shares of cancer therapies developer Senti Biosciences <span>SNTI.O</span> rise 1.1% to $1.70 in premarket</p><p>** H.C. Wainwright starts coverage with \"Buy\" rating and price target $12, a ~614% upside to the stock's last close</p><p>** Brokerage says Senti's new cell therapy helped patients with tough-to-treat blood cancer</p><p>** It believes co's therapy platform \"has the potential to treat several cancer types, including hematologic malignancies and solid tumors\"</p><p>** SNTI is developing a cell therapy to treat acute myeloid leukemia, a fast-growing blood cancer with limited treatment options</p><p>** 2 of 2 brokerages rate the stock 'buy' or higher, none 'hold' or 'sell'; their median price target is $13.50</p><p>** Up to last close, stock has fallen ~52% YTD</p><p>(Reporting by Sahil Pandey in Bengaluru)</p><p>((Sahil.Pandey@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-H.C. Wainwright initiates Senti Biosciences with 'Buy' on cell therapy hopes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-H.C. Wainwright initiates Senti Biosciences with 'Buy' on cell therapy hopes\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-14 21:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-H.C. Wainwright initiates <a href=\"https://laohu8.com/S/SNTI\">Senti Biosciences</a> with 'Buy' on cell therapy hopes</title></head><body><p>** Shares of cancer therapies developer Senti Biosciences <span>SNTI.O</span> rise 1.1% to $1.70 in premarket</p><p>** H.C. Wainwright starts coverage with \"Buy\" rating and price target $12, a ~614% upside to the stock's last close</p><p>** Brokerage says Senti's new cell therapy helped patients with tough-to-treat blood cancer</p><p>** It believes co's therapy platform \"has the potential to treat several cancer types, including hematologic malignancies and solid tumors\"</p><p>** SNTI is developing a cell therapy to treat acute myeloid leukemia, a fast-growing blood cancer with limited treatment options</p><p>** 2 of 2 brokerages rate the stock 'buy' or higher, none 'hold' or 'sell'; their median price target is $13.50</p><p>** Up to last close, stock has fallen ~52% YTD</p><p>(Reporting by Sahil Pandey in Bengaluru)</p><p>((Sahil.Pandey@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nL3N3VV0MP:1","article_id":"2575213041","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575213041","pubTimestamp":1760447221,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-H.C. Wainwright initiates Senti Biosciences with 'Buy' on cell therapy hopes** Shares of cancer therapies developer Senti Biosciences SNTI.O rise 1.1% to $1.70 in premarket** H.C. Wainwright starts coverage with \"Buy\" rating and price target $12, a ~614% upside to the stock's last close** Brokerage says Senti's new cell therapy helped patients with tough-to-treat blood cancer** It believes co's therapy platform \"has the potential to treat several cancer types, including hematologic malignancies and solid tumors\"** SNTI is developing a cell therapy to treat acute myeloid leukemia, a fast-growing blood cancer with limited treatment options** 2 of 2 brokerages rate the stock 'buy' or higher, none 'hold' or 'sell'; their median price target is $13.50** Up to last close, stock has fallen ~52% YTD","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4539":"次新股","SNTI":"Senti Biosciences, Inc."},"translate_title":"巴斯-H.C。Wainwright对Senti Biosciences提出“买入”细胞治疗希望","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNTI":0.9},"content_text":"BUZZ-H.C. Wainwright initiates Senti Biosciences with 'Buy' on cell therapy hopes** Shares of cancer therapies developer Senti Biosciences SNTI.O rise 1.1% to $1.70 in premarket** H.C. Wainwright starts coverage with \"Buy\" rating and price target $12, a ~614% upside to the stock's last close** Brokerage says Senti's new cell therapy helped patients with tough-to-treat blood cancer** It believes co's therapy platform \"has the potential to treat several cancer types, including hematologic malignancies and solid tumors\"** SNTI is developing a cell therapy to treat acute myeloid leukemia, a fast-growing blood cancer with limited treatment options** 2 of 2 brokerages rate the stock 'buy' or higher, none 'hold' or 'sell'; their median price target is $13.50** Up to last close, stock has fallen ~52% YTD(Reporting by Sahil Pandey in Bengaluru)((Sahil.Pandey@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2575213041","isCrawlerRequest":true}